Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Y0001516

Rivastigmine hydrogen tartrate

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Rivastigmine tartrate, ENA-713, Ethylmethyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester, N-Ethyl-N-methyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester tartrate, S-Rivastigmine tartrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C14H22N2O2 · C4H6O6
Número de CAS:
Peso molecular:
400.42
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

rivastigmine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N([C@@H](C)c1cc(ccc1)OC(=O)N(CC)C)(C)C.O[C@@H]([C@H](O)C(=O)O)C(=O)O

InChI

1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1

InChI key

GWHQHAUAXRMMOT-RWALOXMOSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Rivastigmine hydrogen tartrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor that enhances cognitive function in patients with Alzheimer′s and Parkinson′s diseases. Rivastigmine inhibits both butyrylcholinesterase and acetylcholinesterase.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Referencia del producto
Descripción
Precios

pictograms

Skull and crossbonesEnvironment

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 2 Oral - Aquatic Chronic 2

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Katherine L Possin et al.
Movement disorders : official journal of the Movement Disorder Society, 28(10), 1384-1390 (2013-07-13)
The objective of this study was to investigate how acetylcholinesterase inhibitor (ChEI) treatment affects brain function in Parkinson's disease (PD). Twelve patients with PD and either dementia or mild cognitive impairment underwent task-free functional magnetic resonance imaging before and after
Jacqueline Birks et al.
The Cochrane database of systematic reviews, 5(5), CD004744-CD004744 (2013-06-04)
Vascular dementia represents the second most common type of dementia after Alzheimer's disease. In older patients, in particular, the combination of vascular dementia and Alzheimer's disease is common, and is referred to as mixed dementia. The classification of vascular dementia
Kevin R Peters
Journal of the American Geriatrics Society, 61(7), 1170-1174 (2013-05-29)
To highlight the utility of using an effect size analysis to communicate the effectiveness of treatment interventions. Secondary analysis. Previously published systematic review on cholinesterase inhibitors (ChEIs) in Alzheimer's disease. Individuals with mild to moderate Alzheimer's disease. Six-month randomized controlled
Carina Wattmo et al.
Clinical interventions in aging, 8, 329-339 (2013-05-18)
To investigate the long-term effects of cholinesterase inhibitor (ChEI) therapy and the influence of sociodemographic and clinical factors on the use of community-based home help services (HHS) by patients with Alzheimer's disease (AD). This 3-year, prospective, multicenter study included 880
Nastaran Majdi Nasab et al.
JPMA. The Journal of the Pakistan Medical Association, 62(7), 677-680 (2013-07-23)
To assess the efficacy of the Ginkgo biloba in patients with dementia of the Alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment compared with rivastigmine. Total 56 patients aged 50-75 years, suffering from dementia

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico